Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ypsomed Holding AG's revenue for the
six
months ended in Mar. 2026 was CHF368.3 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was CHF731.0 Mil.
Ypsomed Holding AG's Revenue per Share for the
six
months ended in Mar. 2026 was CHF27.14.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF53.71.
Warning Sign:
Ypsomed Holding AG revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Ypsomed Holding AG was -2.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 13.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 11.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 5.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Ypsomed Holding AG's highest 3-Year average Revenue per Share Growth Rate was 34.00% per year. The lowest was -91.60% per year. And the median was 5.95% per year.
Ypsomed Holding AG (XSWX:YPSN) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Ypsomed Holding AG Revenue Related Terms
Ypsomed Holding AG Revenue Historical Data
* Premium members only.
The historical data trend for Ypsomed Holding AG's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Ypsomed Holding AG's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ypsomed Holding AG Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ypsomed Holding AG's Revenue distribution charts can be found below:
* The bar in red indicates where Ypsomed Holding AG's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF731.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ypsomed Holding AG (XSWX:YPSN) has a Revenue of CHF731.0 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Ypsomed Holding AG and its competitors.
Is Ypsomed Holding AG's Revenue too high?
Ypsomed Holding AG's current Revenue is CHF731.0 Mil. Overall, Ypsomed Holding AG has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ypsomed Holding AG's Revenue compare to ISRG and BDX?
Ypsomed Holding AG's Revenue of CHF731.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Ypsomed Holding AG and its competitors. Ypsomed Holding AG's current Revenue is CHF731.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ypsomed Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Ypsomed Holding AG (XSWX:YPSN) is currently considered Fairly Valued. The stock's GF Value™ is CHF396.57, compared to a current price of CHF375.40 — trading 5.3% below its estimated fair value. The current Revenue is CHF731.0 Mil. Ypsomed Holding AG's overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Ypsomed Holding AG (XSWX:YPSN), the current Revenue is CHF731.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ypsomed Holding AG (XSWX:YPSN) Overvalued in 2026?
Based on GuruFocus' analysis, Ypsomed Holding AG stock appears to be undervalued.
The current stock price of CHF375.40 is trading 5.3% below its estimated GF Value™ of CHF396.57.
GuruFocus considers Ypsomed Holding AG to be Fairly Valued.
Key valuation signals for XSWX:YPSN:
Revenue: CHF731.0 Mil
GF Value™: CHF396.57 vs. price of CHF375.40 (5.3% below fair value)
No single metric tells the full story. See the XSWX:YPSN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a click-on function. The company operates under two reportable segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care.
92GF Score
Get the complete analysis for XSWX:YPSN
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:YPSN has been successfully added to your 
